secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K
Filed at:   2022-07-25T23:59:59+00:00
Accession:  0001193125-22-200476
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD extends loan maturity to July 27, appoints CRO, explores Chapter 11
--------------------------------------------------------------------------------

- Amendment No. 13 extends Financing Agreement maturity to July 27, 2022.
- Company pays Lenders $2.9 million interest payment as part of amendment.
- Jeffrey Varsalone of G2 Capital Advisors appointed as Chief Restructuring Officer.
- Board evaluating all options including refinancing, strategic alternatives, and Chapter 11.
- Company intends to maintain normal operations while evaluating options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000119312522200476/0001193125-22-200476-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000119312522200476/d387303d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-200476

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer